Safety outcomes during pediatric GH therapy: final results from the prospective GeNeSIS observational program.

Conclusions: GeNeSIS data support the favourable safety profile of pediatric GH treatment. Overall risk for death or primary cancer was not elevated in GH-treated children, and no hemorrhagic strokes occurred in patients without risk factors. T2DM incidence was elevated compared to the general population, but most cases had diabetes risk factors.
PMID: 30219920 [PubMed - as supplied by publisher]

Source: The Journal of Clinical Endocrinology and Metabolism - September 13, 2018 Category: Endocrinology Authors: Child CJ, Zimmermann AG, Chrousos GP, Cummings E, Deal CL, Hasegawa T, Jia N, Lawrence S, Linglart A, Loche S, Maghnie M, Pérez Sánchez J, Polak M, Predieri B, Richter-Unruh A, Rosenfeld RG, Yeste D, Yorifuji T, Blum WF Tags: J Clin Endocrinol Metab Source Type: research